Cocrystal Pharma, Inc. 8-K

What Happened
Cocrystal Pharma, Inc. announced on April 30, 2026 (via an 8-K, Item 7.01), that the mechanism of action and clinical advancement of its first oral protease inhibitor, CDI-988, were featured in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The company furnished a related press release as Exhibit 99.1 to the filing.

Key Details

• Filing date: April 30, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Event: Oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague.
• Subject: Mechanism of action and clinical advancement of CDI-988, described as the company’s first oral protease inhibitor.
• Press release summarizing the presentation was furnished as Exhibit 99.1 to the 8-K.

Why It Matters
This is a scientific and clinical update—filed under Regulation FD to ensure broad public disclosure—rather than a financial report. For investors, the presentation signals that CDI-988 remains an active development program and that the company is communicating progress to the scientific community. Shareholders should watch for subsequent filings or press releases with concrete clinical data, trial results, or regulatory milestones that could have direct implications for the company’s development timeline and valuation.